Liquidia (NASDAQ:LQDA) Price Target Raised to $92.00

Key Points

• Bank of America raised Liquidia’s price target to $92 from $79 while maintaining a Neutral rating, implying 16.77% upside from the prior close. Analysts overall rate the stock a Moderate Buy with a consensus target of $91.08.
• Liquidia’s latest quarter showed strong growth, with revenue rising 1,842.1% year over year to $171.68 million and net income reaching $74.7 million, though EPS of $0.74 slightly missed the $0.76 consensus estimate.
• Valuation and insider selling remain risks: shares trade near their 12-month high at a price-to-earnings ratio above 560, while insiders have sold approximately $124.4 million of stock over the past 90 days.

Liquidia (NASDAQ:LQDA - Get Free Report) had its target price lifted by equities research analysts at Bank of America from $79.00 to $92.00 in a research note issued to investors on Thursday,Benzinga reports. The brokerage presently has a "neutral" rating on the stock. Bank of America's price target would suggest a potential upside of 16.77% from the company's previous close.

Other equities analysts also recently issued reports about the stock. Stephens set a $130.00 price objective on shares of Liquidia in a research note on Friday, July 24th. HC Wainwright set a $36.00 target price on Liquidia in a report on Friday, July 24th. Wall Street Zen cut Liquidia from a "strong-buy" rating to a "buy" rating in a research report on Saturday, June 27th. Oppenheimer set a $75.00 price target on Liquidia in a report on Friday, June 5th. Finally, Raymond James Financial reissued a "strong-buy" rating and issued a $68.00 price target on shares of Liquidia in a research report on Thursday, June 4th. Two research analysts have rated the stock with a Strong Buy rating, five have given a Buy rating, two have issued a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $91.08.

Liquidia Price Performance

LQDA opened at $78.79 on Thursday. The company has a market capitalization of $7.01 billion, a price-to-earnings ratio of 562.83 and a beta of 0.58. The company has a current ratio of 2.22, a quick ratio of 2.03 and a debt-to-equity ratio of 1.18. Liquidia has a 12-month low of $21.15 and a 12-month high of $93.61. The business's fifty day simple moving average is $78.22 and its 200-day simple moving average is $54.77.

Liquidia (NASDAQ:LQDA - Get Free Report) last released its quarterly earnings data on Wednesday, August 12th. The company reported $0.74 earnings per share for the quarter, missing analysts' consensus estimates of $0.76 by ($0.02). Liquidia had a return on equity of 46.82% and a net margin of 7.74%.The business had revenue of $171.68 million during the quarter, compared to analysts' expectations of $168.48 million. During the same period last year, the company earned ($0.49) earnings per share. The firm's revenue was up 1842.1% compared to the same quarter last year. On average, equities research analysts anticipate that Liquidia will post 3.02 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, insider Jason Adair sold 688 shares of the stock in a transaction that occurred on Monday, July 27th. The shares were sold at an average price of $87.53, for a total value of $60,220.64. Following the completion of the transaction, the insider directly owned 216,438 shares of the company's stock, valued at $18,944,818.14. This trade represents a 0.32% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Sanjeev Khindri sold 1,185 shares of the company's stock in a transaction that occurred on Monday, July 13th. The shares were sold at an average price of $71.51, for a total transaction of $84,739.35. Following the transaction, the insider owned 65,947 shares in the company, valued at $4,715,869.97. The trade was a 1.77% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders have sold 1,781,861 shares of company stock valued at $124,407,112. 25.60% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Liquidia

Several hedge funds and other institutional investors have recently bought and sold shares of LQDA. Covestor Ltd grew its position in shares of Liquidia by 41.9% during the 4th quarter. Covestor Ltd now owns 1,216 shares of the company's stock valued at $42,000 after acquiring an additional 359 shares during the period. PNC Financial Services Group Inc. boosted its position in Liquidia by 7.2% during the fourth quarter. PNC Financial Services Group Inc. now owns 6,304 shares of the company's stock worth $217,000 after purchasing an additional 422 shares in the last quarter. Quantinno Capital Management LP grew its holdings in Liquidia by 3.6% in the first quarter. Quantinno Capital Management LP now owns 17,165 shares of the company's stock valued at $648,000 after purchasing an additional 589 shares during the period. Northwestern Mutual Wealth Management Co. acquired a new stake in Liquidia in the fourth quarter valued at approximately $25,000. Finally, ProShare Advisors LLC increased its position in shares of Liquidia by 7.1% in the fourth quarter. ProShare Advisors LLC now owns 11,756 shares of the company's stock valued at $405,000 after buying an additional 775 shares in the last quarter. Institutional investors and hedge funds own 64.54% of the company's stock.

More Liquidia News

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: YUTREPIA sales accelerated: Net product sales reached approximately $170.4 million, up 31% sequentially, while total revenue of $171.7 million exceeded the $168.5 million consensus estimate. Management said demand for the inhaled lung-disease treatment continues to grow, with about 5,900 prescriptions and more than 5,000 patients treated since launch. Liquidia Corporation Reports Second Quarter 2026 Financial Results
• Positive Sentiment: Profitability and liquidity improved: Liquidia reported $74.7 million of net income, $96.3 million of adjusted EBITDA and its fourth consecutive quarter of improving profitability. Cash increased to approximately $284.2 million, supporting commercialization and development efforts.
• Positive Sentiment: Analyst targets increased: Needham raised its price target from $70 to $110 and BTIG lifted its target from $109 to $111; both firms maintain Buy ratings. Lifesci Capital reiterated Market Perform with a $90 target. Analyst price-target updates
• Neutral Sentiment: Future investment remains elevated: Liquidia is advancing 10 clinical studies for YUTREPIA and L606, but research and development spending rose to $17.2 million from $6.0 million a year earlier. Management reaffirmed its goal of exceeding $1 billion in net revenue in 2027.
• Negative Sentiment: EPS slightly missed expectations: Diluted earnings were $0.74 per share versus the $0.76 consensus estimate cited by several reports, even though the result improved sharply from a $0.49 loss in the prior-year quarter. The earnings miss likely outweighed the revenue beat for short-term traders.
• Negative Sentiment: Valuation and insider selling may pressure the stock: Liquidia trades at a very high earnings multiple after a major run-up, creating a greater risk of profit-taking. Recent data also shows substantially more insider selling than buying, which may weigh on investor sentiment.

Liquidia Company Profile

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company's lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source